For the quarter ending 2025-09-30, EDIT made $7,543K in revenue. -$25,117K in net income. Net profit margin of -332.98%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration and other research and development revenues | 7,543 | 3,578 | 4,658 | 61 |
| Research and development | 19,775 | 16,181 | 26,593 | 47,639 |
| General and administrative | 12,316 | 12,859 | 13,375 | 18,088 |
| Restructuring and impairment charges | 0 | 26,082 | 40,853 | - |
| Total operating expenses | 32,091 | 55,122 | 80,821 | 65,727 |
| Operating loss | -24,548 | -51,544 | -76,163 | -65,666 |
| Interest expense related to sale of future revenues | 2,399 | 2,020 | 2,216 | - |
| Interest income, net | 1,831 | 2,087 | 2,716 | 3,530 |
| Other expense, net | -1 | -1,758 | -425 | -5 |
| Total other (expense) income, net | -569 | -1,691 | 75 | 3,525 |
| Net loss | -25,117 | -53,235 | -76,088 | -62,141 |
| Net loss per share, basic (in dollars per share) | -0.28 | -0.63 | -0.92 | -0.75 |
| Net loss per share, diluted (in dollars per share) | -0.28 | -0.63 | -0.92 | -0.75 |
| Weighted-average common shares outstanding, basic (in shares) | 90,090,397 | 84,412,200 | 83,055,066 | 82,485,199 |
| Weighted-average common shares outstanding, diluted (in shares) | 90,090,397 | 84,412,200 | 83,055,066 | 82,485,199 |
Editas Medicine, Inc. (EDIT)
Editas Medicine, Inc. (EDIT)